biotech / news / / CNBC TV18
AstraZeneca and GSK beat first quarter earnings forecasts, driven by strong cancer and HIV drugs.
AstraZeneca's Q1 earnings per share were $2.58, surpassing analyst forecasts.
KEY POINTS
- Strong sales of Imfinzi and other oncology drugs support AstraZeneca's $80 billion revenue target by 2030.
- GSK's Q1 adjusted earnings rose to 46.5 pence, exceeding estimates of 43.2 pence.
- GSK's stock rose nearly 34% following the announcement of Luke Miels as incoming CEO.
COMPANIES
Summarized by Newsio from CNBC TV18. How we summarize →